Reversible platelet inhibition

Reversible Platelet Inhibition

Reversible platelet inhibition refers to temporary, non-covalent blockade of platelet activation pathways, allowing recovery of platelet function after drug clearance. This contrasts with irreversible agents (e.g., aspirin, clopidogrel), which permanently inactivate platelets for their lifespan (7–10 days).

1️⃣ P2Y12 Receptor Inhibitors (Reversible)

These block the ADP P2Y12 receptor on platelets, preventing GPIIb/IIIa activation and aggregation.

🔹 Ticagrelor

Cyclopentyl-triazolo-pyrimidine (not a thienopyridine)
Direct-acting (no metabolic activation required)
Rapid onset (~30 min)
Offset: 3–5 days
Additional effect: ↑ Adenosine levels (via ENT1 inhibition)
Key trial: PLATO trial
Adverse effects: Dyspnea, ventricular pauses

🔹 Cangrelor

IV, direct, reversible
Immediate onset (within 2 minutes)
Very short half-life (3–6 min)
Platelet recovery: 30–60 min after stopping
Used during PCI when oral P2Y12 not feasible
Trial: CHAMPION PHOENIX trial

2️⃣ GPIIb/IIIa Inhibitors (Functionally Reversible)

Block final common pathway of aggregation (fibrinogen binding).

🔹 Abciximab

Monoclonal antibody
Strong receptor affinity
Platelet recovery: 24–48 hrs
Functionally semi-irreversible (tight binding)

🔹 Eptifibatide

Cyclic heptapeptide
Reversible
Recovery: 4–8 hrs

🔹 Tirofiban

Non-peptide small molecule
Reversible
Recovery: 4–8 hrs

3️⃣ PAR-1 (Thrombin Receptor) Antagonist

🔹 Vorapaxar

Reversible binding
Very long half-life (~8 days)
Clinically behaves as prolonged inhibitor
Trial: TRA 2°P-TIMI 50 trial

4️⃣ Phosphodiesterase Inhibitors

Increase cAMP → inhibit platelet activation.

🔹 Dipyridamole

Reversible
Often combined with aspirin (e.g., stroke prevention)

🔹 Cilostazol

Reversible
Used in PAD, sometimes in triple therapy

⚖️ Reversible vs Irreversible (Exam Comparison)

Feature	Reversible	Irreversible
Binding	Non-covalent	Covalent
Platelet recovery	After drug clearance	New platelet production
Perioperative management	Short interruption sufficient	5–7 days required
Example	Ticagrelor	Aspirin, Clopidogrel

🔬 High-Yield Clinical Points (NEET-SS / DM Cardiology)

Cangrelor is ideal when urgent PCI is needed and oral agents cannot be given.
Ticagrelor causes dyspnea via adenosine reuptake inhibition.
Abciximab has prolonged platelet inhibition despite short plasma half-life.
For urgent CABG: stop ticagrelor 3 days prior; clopidogrel 5 days.
Platelet transfusion reverses irreversible agents more effectively than ticagrelor (due to circulating drug).

Q1. The reversible P2Y12 inhibitor that increases extracellular adenosine is:

A. Ticagrelor

B. Clopidogrel

C. Prasugrel

D. Cangrelor

Ticagrelor inhibits ENT1 → ↑ adenosine → dyspnea, bradyarrhythmias.

Q2. Platelet recovery after stopping IV Cangrelor occurs in:

A. 6–8 h

B. 12 h

C. 30–60 min

D. 24 h

Cangrelor half-life 3–6 min → recovery within 1 hour.

Q3. Abciximab causes prolonged platelet inhibition because:

A. Covalent binding

B. High receptor affinity

C. Active metabolites

D. Renal clearance

Abciximab tightly binds GP IIb/IIIa → 24–48 h inhibition.

Q4. The only IV reversible P2Y12 inhibitor is:

A. Ticagrelor

B. Cangrelor

C. Vorapaxar

D. Eptifibatide

Cangrelor is IV, direct, rapidly reversible.

Q5. Ticagrelor should be stopped before CABG for:

A. 24 h

B. 48 h

C. 3 days

D. 7 days

Guidelines recommend 3-day discontinuation.

Q6. Direct-acting P2Y12 inhibitor:

A. Ticagrelor

B. Clopidogrel

C. Prasugrel

D. Ticlopidine

Thienopyridines require CYP activation; ticagrelor does not.

Q7. Recovery after stopping Eptifibatide:

A. 24–48 h

B. 4–8 h

C. 72 h

D. 1 h

Small molecule GP IIb/IIIa inhibitors reverse in 4–8 h.

Q8. Cangrelor is metabolized by:

A. Plasma dephosphorylation

B. CYP3A4

C. Renal esterases

D. Hepatic glucuronidation

Rapid dephosphorylation → ultra-short half-life.

Q9. Vorapaxar blocks:

A. P2Y12

B. COX-1

C. PAR-1

D. GPIIb/IIIa

Vorapaxar is a PAR-1 thrombin receptor antagonist.

Q10. Platelet transfusion reverses which most effectively?

A. Ticagrelor

B. Cangrelor

C. Aspirin

D. Abciximab

Irreversible COX inhibition is replaced by new platelets.

Q11. Dyspnea with Ticagrelor is due to:

A. Adenosine reuptake inhibition

B. β2 stimulation

C. Histamine release

D. COX inhibition

ENT1 inhibition ↑ adenosine levels.

Q12. Half-life of Cangrelor:

A. 3–6 min

B. 1 h

C. 6 h

D. 24 h

Ultra-short acting IV P2Y12 inhibitor.

Q13. Cilostazol inhibits:

A. COX-1

B. PDE-3

C. PAR-1

D. P2Y12

↑ cAMP → platelet inhibition.

Q14. GP IIb/IIIa inhibitors block:

A. Fibrinogen binding

B. Thromboxane synthesis

C. ADP release

D. Collagen exposure

Final common pathway blockade.

Q15. Abciximab recovery time:

A. 24–48 h

B. 1 h

C. 4 h

D. 5 days

Due to tight receptor binding.

Q16. Reversible binding implies:

A. Non-covalent interaction

B. Permanent receptor inactivation

C. Platelet destruction

D. DNA modification

Reversible inhibitors dissociate after clearance.

Q17. Best agent for bridging during urgent PCI:

A. Cangrelor

B. Prasugrel

C. Aspirin

D. Vorapaxar

Immediate onset and rapid offset.

Q18. Dipyridamole works by:

A. PDE inhibition

B. COX inhibition

C. PAR-1 block

D. P2Y12 block

↑ cAMP → platelet inhibition.

Q19. Ticagrelor belongs to:

A. Thienopyridine

B. Cyclopentyl-triazolo-pyrimidine

C. Monoclonal antibody

D. Peptide mimetic

Structurally distinct from thienopyridines.

Q20. Which agent has the longest functional inhibition despite reversible binding?

A. Cangrelor

B. Eptifibatide

C. Vorapaxar

D. Dipyridamole

Vorapaxar has very long half-life (~8 days) despite reversible receptor binding.

Case-Vignette Ultra-Hard MCQs (Q1–Q20)

Q1

A 64-year-old STEMI patient vomits immediately after receiving oral Ticagrelor loading. He is now in the cath lab. Best next step?

A. Reload ticagrelor
B. Give clopidogrel
C. Start IV Cangrelor
D. Proceed without P2Y12

Answer: C
Immediate IV platelet inhibition is required; absorption is unreliable.

Q2

A patient on ticagrelor requires emergency CABG 24 hours after last dose. Platelet transfusion is given. Persistent inhibition occurs because:

A. Irreversible binding
B. Active metabolites
C. Circulating free drug
D. COX-1 suppression

Answer: C
Ticagrelor remains in plasma → inhibits transfused platelets.

Q3

NSTEMI on clopidogrel (5 days stopped) scheduled for high-risk PCI. Strategy to maintain inhibition until wire crossing?

A. Restart clopidogrel morning of PCI
B. No therapy needed
C. Start IV cangrelor bridge
D. Start warfarin

Answer: C
Bridging preserves platelet inhibition without delayed offset.

Q4

During cangrelor infusion, oral ticagrelor is administered. When should cangrelor be stopped?

A. Immediately
B. After 30 minutes
C. After ticagrelor loading complete
D. 6 hours later

Answer: C
Overlap until oral agent achieves effect.

Q5

A patient with prior intracranial hemorrhage is considered for Vorapaxar post-MI. Correct decision?

A. Safe if low dose
B. Safe with PPI
C. Contraindicated
D. Use with aspirin only

Answer: C
Vorapaxar is contraindicated with prior stroke/ICH.

Q6

STEMI, cardiogenic shock, intubated. NG tube malfunctioning. Best antiplatelet strategy?

A. Crush ticagrelor
B. Clopidogrel IV
C. IV cangrelor
D. Eptifibatide alone

Answer: C
Only IV P2Y12 available.

Q7

Platelet function normalizes 45 min after stopping which drug?

A. Abciximab
B. Ticagrelor
C. Cangrelor
D. Eptifibatide

Answer: C

Q8

Which GP IIb/IIIa inhibitor has longest receptor occupancy despite short plasma half-life?

A. Eptifibatide
B. Tirofiban
C. Abciximab
D. Cangrelor

Answer: C

Q9

Elective PCI patient stopped ticagrelor 2 days ago for surgery. Procedure now urgent. Optimal plan?

A. Wait 24 more hours
B. Load prasugrel
C. Start IV cangrelor
D. Give aspirin only

Answer: C

Q10

Dyspnea with ticagrelor is mediated via:

A. β-agonism
B. Histamine
C. Adenosine elevation
D. Serotonin release

Answer: C

Q11

Patient receives cangrelor and then clopidogrel loading during infusion. Effect?

A. Synergistic
B. No interaction
C. Reduced clopidogrel activation
D. Increased bleeding

Answer: C
Cangrelor competitively blocks P2Y12 receptor → prevents clopidogrel active metabolite binding.

Q12

Renal failure patient undergoing PCI. Preferred reversible GP IIb/IIIa inhibitor?

A. Abciximab
B. Eptifibatide
C. Tirofiban
D. None

Answer: A
Small molecules are renally cleared.

Q13

Bridge therapy is most useful when:

A. Elective PCI 7 days later
B. High thrombotic risk & oral interruption
C. Low bleeding risk
D. Aspirin stopped

Answer: B

Q14

Which agent requires hepatic activation?

A. Ticagrelor
B. Cangrelor
C. Clopidogrel
D. Eptifibatide

Answer: C

Q15

A patient on cangrelor develops thrombocytopenia within hours. Most likely mechanism?

A. Immune complex
B. Direct receptor blockade
C. HIT
D. Bone marrow suppression

Answer: A
Similar to abciximab immune-mediated reaction.

Q16

Which drug has longest half-life but reversible receptor binding?

A. Cangrelor
B. Ticagrelor
C. Vorapaxar
D. Dipyridamole

Answer: C

Q17

Optimal timing of clopidogrel loading when stopping cangrelor?

A. 1 hr before stopping
B. At infusion discontinuation
C. 6 hr after stopping
D. Next day

Answer: B

Q18

Which drug acts via PDE-3 inhibition increasing cAMP?

A. Ticagrelor
B. Cilostazol
C. Vorapaxar
D. Cangrelor

Answer: B

Q19

Emergency PCI after prasugrel loading 2 hours earlier. Vomited dose. Best step?

A. Reload prasugrel
B. Switch to ticagrelor
C. Start IV cangrelor
D. GP IIb/IIIa bolus only

Answer: C

Q20

Major advantage of reversible inhibition in perioperative planning:

A. Less bleeding
B. No transfusion needed
C. Faster offset without new platelets
D. No monitoring required

Answer: C

High-Yield Trap Summary

Cangrelor blocks binding of clopidogrel active metabolite if overlapped improperly.
Ticagrelor → transfusion ineffective early (circulating drug).
Abciximab → longest receptor occupancy.
Vorapaxar → contraindicated in prior stroke/ICH.
Bridge = high thrombotic risk + oral interruption.

Reversible platelet inhibition